ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41476672

The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC.

Kang Y and 4 others. Breast Cancer (Dove Med Press), 2025. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC. Papers, record 41476672. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41476672

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC.
PubMed
Journal
Breast Cancer (Dove Med Press)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-01-03
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kang YYujuanhttps://orcid.org/0000-0001-8344-6005
2Liu YYanqing
3Liang ZZhi
4Zhang SSong
5Qiao GGuangdong

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References227

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,692,516Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation.Front Oncol2021https://conductscience.org/library/papers/34692516PubMed
230,679,171Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.Cancer Discov2019https://conductscience.org/library/papers/30679171PubMed
330,798,356T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.J Cancer Res Clin Oncol2019https://conductscience.org/library/papers/30798356PubMed
421,884,205Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.Histopathology2011https://conductscience.org/library/papers/21884205PubMed
536,568,247Ferroptosis and triple-negative breast cancer: Potential therapeutic targets.Front Oncol2022https://conductscience.org/library/papers/36568247PubMed
635,414,060Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.Cell Death Dis2022https://conductscience.org/library/papers/35414060PubMed
720,164,688Triple-negative breast cancer: role of antiangiogenic agents.Cancer J2010https://conductscience.org/library/papers/20164688PubMed
831,927,455Triple negative breast cancer: A thorough review of biomarkers.Crit Rev Oncol Hematol2020https://conductscience.org/library/papers/31927455PubMed
933,352,844The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.Pharmaceuticals (Basel)2020https://conductscience.org/library/papers/33352844PubMed
1022,258,607The DNA damage response and cancer therapy.Nature2012https://conductscience.org/library/papers/22258607PubMed

1 to 10 of 227

See all 227 references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn PapersSource
42,870,830MIF-mediated intercellular crosstalk drives antigen-presenting-like cancer-associated fibroblast differentiation in triple-negative breast cancer via TGF-β signaling.Transl Cancer Res2026https://conductscience.org/library/papers/42870830PubMed
42,858,231
RecurIndex-derived molecular features associated with total pathological complete response in triple-negative breast cancer: An exploratory prospective cohort study with single-cell transcriptomic contextualization.
Cancer Biol Ther2026https://conductscience.org/library/papers/42858231PubMed

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ESR12,099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
PGR5,241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41476672

GET https://conductscience.org/api/papers/v1/41476672/references?page=2

API referenceFor AI assistants